NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis $2.98 +0.01 (+0.17%) As of 10:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lipocine Stock (NASDAQ:LPCN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lipocine alerts:Sign Up Key Stats Today's Range$2.98▼$2.9850-Day Range$2.93▼$3.4452-Week Range$2.68▼$6.17Volume134 shsAverage Volume33,186 shsMarket Capitalization$16.18 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingStrong Buy Company Overview Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. Read More Lipocine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreLPCN MarketRank™: Lipocine scored higher than 48% of companies evaluated by MarketBeat, and ranked 589th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingLipocine has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLipocine has only been the subject of 2 research reports in the past 90 days.Read more about Lipocine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipocine's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.87% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently decreased by 1.99%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.87% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently decreased by 1.99%, indicating that investor sentiment is improving. News and Social Media1.3 / 5News Sentiment-0.61 News SentimentLipocine has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lipocine this week, compared to 1 article on an average week.Search Interest1 people have searched for LPCN on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.35% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions.Read more about Lipocine's insider trading history. Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LPCN Stock News HeadlinesLipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025August 26 at 8:00 AM | prnewswire.comHC Wainwright Issues Negative Outlook for Lipocine EarningsAugust 24, 2025 | americanbankingnews.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 29 at 2:00 AM | Timothy Sykes (Ad)Lipocine (NASDAQ:LPCN) Given "Buy" Rating at HC WainwrightAugust 22, 2025 | americanbankingnews.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2025August 5, 2025 | prnewswire.comLipocine doses first patient in phase 3 trial for oral PPD treatmentJune 28, 2025 | uk.investing.comLipocine begins dosing in Phase III postpartum depression trial of LPCN 1154June 27, 2025 | msn.comLipocine Begins Phase 3 Trial for LPCN 1154June 26, 2025 | tipranks.comSee More Headlines LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed this year? Lipocine's stock was trading at $4.88 at the start of the year. Since then, LPCN shares have decreased by 38.9% and is now trading at $2.98. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its earnings results on Tuesday, August, 5th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). The specialty pharmaceutical company earned $0.62 million during the quarter, compared to analysts' expectations of $1 million. When did Lipocine's stock split? Shares of Lipocine reverse split before market open on Friday, May 12th 2023.The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA). Company Calendar Last Earnings8/05/2025Today8/29/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPCN CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees10Year Founded1997Price Target and Rating Average Price Target for Lipocine$9.00 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+201.5%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$10 thousand Net MarginsN/A Pretax Margin-107.13% Return on Equity-23.59% Return on Assets-21.91% Debt Debt-to-Equity RatioN/A Current Ratio12.71 Quick Ratio12.71 Sales & Book Value Annual Sales$11.20 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book0.94Miscellaneous Outstanding Shares5,420,000Free Float5,075,000Market Cap$16.18 million OptionableNo Data Beta1.24 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LPCN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.